Indications for islet or pancreatic transplantation: Statement of the TREPID working group on behalf of the Societe francophone du diabete (SFD), Societe francaise d'endocrinologie (SFE), Societe francophone de transplantation (SFT) and Societe francaise de nephrologie - dialyse - transplantation (SFNDT)

Details

Serval ID
serval:BIB_A1A57582177C
Type
Article: article from journal or magazin.
Collection
Publications
Title
Indications for islet or pancreatic transplantation: Statement of the TREPID working group on behalf of the Societe francophone du diabete (SFD), Societe francaise d'endocrinologie (SFE), Societe francophone de transplantation (SFT) and Societe francaise de nephrologie - dialyse - transplantation (SFNDT)
Journal
Diabetes Metab
Author(s)
Wojtusciszyn A., Branchereau J., Esposito L., Badet L., Buron F., Chetboun M., Kessler L., Morelon E., Berney T., Pattou F., Benhamou P. Y., Vantyghem M. C.
Working group(s)
Trepid group
ISSN
1878-1780 (Electronic)
ISSN-L
1262-3636
Publication state
Published
Issued date
06/2019
Volume
45
Number
3
Pages
224-237
Language
english
Notes
Wojtusciszyn, A
Branchereau, J
Esposito, L
Badet, L
Buron, F
Chetboun, M
Kessler, L
Morelon, E
Berney, T
Pattou, F
Benhamou, P-Y
Vantyghem, M-C
eng
Practice Guideline
Review
France
Diabetes Metab. 2019 Jun;45(3):224-237. doi: 10.1016/j.diabet.2018.07.006. Epub 2018 Sep 14.
Abstract
While either pancreas or pancreatic islet transplantation can restore endogenous insulin secretion in patients with diabetes, no beta-cell replacement strategies are recommended in the literature. For this reason, the aim of this national expert panel statement is to provide information on the different kinds of beta-cell replacement, their benefit-risk ratios and indications for each type of transplantation, according to type of diabetes, its control and association with end-stage renal disease. Allotransplantation requires immunosuppression, a risk that should be weighed against the risks of poor glycaemic control, diabetic lability and severe hypoglycaemia, especially in cases of unawareness. Pancreas transplantation is associated with improvement in diabetic micro- and macro-angiopathy, but has the associated morbidity of major surgery. Islet transplantation is a minimally invasive radiological or mini-surgical procedure involving infusion of purified islets via the hepatic portal vein, but needs to be repeated two or three times to achieve insulin independence and long-term functionality. Simultaneous pancreas-kidney and pancreas after kidney transplantations should be proposed for kidney recipients with type 1 diabetes with no surgical, especially cardiovascular, contraindications. In cases of high surgical risk, islet after or simultaneously with kidney transplantation may be proposed. Pancreas, or more often islet, transplantation alone is appropriate for non-uraemic patients with labile diabetes. Various factors influencing the therapeutic strategy are also detailed in this report.
Keywords
Diabetes Mellitus, Type 1/*surgery, Humans, *Islets of Langerhans Transplantation, *Pancreas Transplantation, Risk Assessment, Risk Factors, Treatment Outcome, *Cell therapy, *Diabetes, *Islet transplantation, *Kidney transplantation, *Type 1 diabetes
Pubmed
Create date
14/06/2021 8:59
Last modification date
18/09/2021 5:38
Usage data